LianBio (NASDAQ:LIAN – Get Free Report) was up 2.5% during mid-day trading on Friday . The company traded as high as $0.30 and last traded at $0.30. Approximately 175,223 shares were traded during trading, a decline of 83% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.29.
LianBio Trading Up 2.5 %
The company’s 50-day moving average is $0.31 and its 200 day moving average is $0.31. The stock has a market capitalization of $32.42 million, a PE ratio of -0.37 and a beta of 0.23.
About LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
Recommended Stories
- Five stocks we like better than LianBio
- How Can Investors Benefit From After-Hours Trading
- California Resources Stock Could Be a Huge Long-Term Winner
- What Are Some of the Best Large-Cap Stocks to Buy?
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.
